ArticleCancer reports (Hoboken, N.J.)2024

Utilization of EGFR, ALK, and BRAF Inhibitors in the Treatment of Lung Cancer in Germany.

Nikolaj Rischke et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.